Vera Therapeutics (VERA) Change in Accured Expenses (2020 - 2026)

Vera Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$437000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 90.86% year-over-year to -$437000.0; the trailing twelve-month figure through Mar 2026 stood at $18.8 million (up 358.67% YoY), and the FY2025 full-year result was $14.4 million, up 100.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$437000.0, down from $7.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $8.1 million in Q2 2025, with the low at -$4.8 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $1.5 million across 5 years, with a median of $474000.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 2964.29% — and 2024, when it surged 776.68%.
• Vera Therapeutics' Change in Accured Expenses stood at $4.7 million in 2022, then slumped by 122.21% to -$1.1 million in 2023, then sank by 257.4% to -$3.8 million in 2024, then surged by 291.35% to $7.2 million in 2025, then plunged by 106.06% to -$437000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$437000.0 (Q1 2026), $7.2 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.